Reducing effect of mangiferin on serum uric acid levels in mice

Pharmaceutical Biology

Volumn 50, Issue 9, 2012, Pages 1177-1182

  Niu, Yanfen ^a   Lu, Wei ^a   Gao, Lihui ^a   Lin, Hua ^a   Liu, Xu ^a   Li, Ling ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Gout; Hyperuricemia; Hyperuricemic mice; Hypouricemic effect; Xanthine dehydrogenase; Xanthine oxidase

Indexed keywords

ALLOPURINOL; BENZBROMARONE; MANGIFERIN; URIC ACID; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HYPERURICEMIA; MALE; MOUSE; NONHUMAN; TOXICITY TESTING; URIC ACID BLOOD LEVEL;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GOUT; GOUT SUPPRESSANTS; HYPERURICEMIA; LIVER; MALE; MICE; MICE, INBRED STRAINS; OXONIC ACID; TIME FACTORS; TOXICITY TESTS, ACUTE; URIC ACID; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE; XANTHONES;

EID: 84865263238     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2012.663763     Document Type: Article

References (30)

1. Bomalaski JS, Clark MA. (2004). Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep, 6, 240-247.
2. Burkhardt S, Reiter RJ, Tan DX, Hardeland R, Cabrera J, Karbownik M. (2001). DNA oxidatively damaged by chromium(III) and H(2) O(2) is protected by the antioxidants melatonin, N(1)-acetyl- N(2)-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol, 33, 775-783.
3. Campion EW, Glynn RJ, DeLabry LO. (1987). Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med, 82, 421-426.
4. Carroll JJ, Coburn H, Douglass R, Babson AL. (1971). A simplified alkaline phosphotungstate assay for uric acid in serum. Clin Chem, 17, 158-160.
5. Cazzaniga G, Terao M, Lo Schiavo P, Galbiati F, Segalla F, Seldin MF, Garattini E. (1994). Chromosomal mapping, isolation, and characterization of the mouse xanthine dehydrogenase gene. Genomics, 23, 390-402.
6. Fang J, Alderman MH . (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992.
7. National Health and Nutrition Examination Survey. JAMA, 283, 2404-2410.
8. Garcia D, Delgado R, Ubeira FM, Leiro J . (2002). Modulation of rat macrophage function by the Mangifera indica L. extracts Vimang and mangiferin. Int Immunopharmacol, 2, 797-806.
9. Ge DD, Zhang Y, Liu EW, Wang T, Hu LM. (2011). Chemical constituents of Mangifera indica leaves (I). Chin Trad Herb Drugs, 42, 428-431.
10. Hair PI, McCormack PL, Keating GM. (2008). Febuxostat. Drugs, 68, 1865-1874.
11. Hall AP, Barry PE, Dawber TR, McNamara PM. (1967). Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med, 42, 27-37.
12. Hall IH, Scoville JP, Reynolds DJ, Simlot R, Duncan P. (1990). Substituted cyclic imides as potential anti-gout agents. Life Sci, 46, 1923-1927.
13. Hayden MR, Tyagi SC . (2004). Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond), 1, 10.
14. Ichida K, Amaya Y, Noda K, Minoshima S, Hosoya T, Sakai O, Shimizu N, Nishino T. (1993). Cloning of the cDNA encoding human xanthine dehydrogenase (oxidase): Structural analysis of the protein and chromosomal location of the gene. Gene, 133, 279-284.
15. Ichiki H, Miura T, Kubo M, Ishihara E, Komatsu Y, Tanigawa K, Okada M . (1998). New antidiabetic compounds, mangiferin and its glucoside. Biol Pharm Bull, 21, 1389-1390.
16. Kong L, Zhou J, Wen Y, Li J, Cheng CH. (2002). Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthine oxidase/dehydrogenase inhibitory activity. Planta Med, 68, 175-178.
17. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. (1999). Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology, 10, 391-397.
18. Minoshima S, Wang Y, Ichida K, Nishino T, Shimizu N. (1995). Mapping of the gene for human xanthine dehydrogenase (oxidase) (XDH) to band p23 of chromosome 2. Cytogenet Cell Genet, 68, 52-53.
19. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ . (2006). A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 290, F625-F631.
20. Puddu PE, Lanti M, Menotti A, Mancini M, Zanchetti A, Cirillo M, Angeletti M, Panarelli W; Gubbio Study Research Group. (2001). Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population study. Acta Cardiol, 56, 243-251.
21. Reinders MK, Jansen TL. (2010). Management of hyperuricemia in gout: Focus on febuxostat. Clin Interv Aging, 5, 7-18.
22. Schlesinger N. (2004). Management of acute and chronic gouty arthritis: Present state-of-the-art. Drugs, 64, 2399-2416.
23. Shoji A, Yamanaka H, Kamatani N. (2004). A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum, 51, 321-325.
24. Singh S, Farhan Asad S, Hadi SM. (1998). Uric acid inhibits l-DOPACU (II) mediated DNA cleavage. Neurosci Lett, 258, 69-72.
25. Stavric B, Clayman S, Gadd RE, Hebert D. (1975). Some in vivo effects in the rat induced by chlorprothixene and potassium oxonate. Pharmacol Res Commun, 7, 117-124.
26. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T. (2000). Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol, 10, 403-409.
27. Yamada H, Kotaki H, Furitsu H, Sawada Y, Iga T. (1999). Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: Study using a rat model of hyperuricemia. Biopharm Drug Dispos, 20, 77-83.
28. Yonetani Y, Iwaki K. (1983). Effects of uricosuric drugs and diuretics on uric acid excretion in oxonate-treated rats. Jpn J Pharmacol, 33, 947-954.
29. Yoshikawa M, Ninomiya K, Shimoda H, Nishida N, Matsuda H . (2002). Hepatoprotective and antioxidative properties of Salacia reticulata: Preventive effects of phenolic constituents on CCl4- induced liver injury in mice. Biol Pharm Bull, 25, 72-76.
30. Yoshimi N, Matsunaga K, Katayama M, Yamada Y, Kuno T, Qiao Z, Hara A, Yamahara J, Mori H . (2001). The inhibitory effects of mangiferin, a naturally occurring glucosylxanthone, in bowel carcinogenesis of male F344 rats. Cancer Lett, 163, 163-170.